8-K: SBC Medical Group Acquires Majority Stake in Waqoo, Inc.

SBC Medical Group Holdings announced the final results of its tender offer for Waqoo, Inc. shares, securing a majority ownership stake.

Summary

• SBC Medical Group Co., Ltd. (SBCMG) successfully completed a tender offer for common stock of Waqoo, Inc. (TSE Growth: 4937), a Japanese medical research and development company.
• The tender offer, conducted from November 14, 2025, to December 12, 2025, was priced at JPY 1,900 per share.
• SBCMG planned to purchase a maximum of 575,000 shares, but 637,817 shares were tendered, exceeding the maximum volume.
• SBCMG will purchase 575,052 shares on a pro rata basis, with settlement scheduled for December 19, 2025.
• Following the tender offer, SBCMG will hold 9,286 voting rights, representing 24.93% ownership of Waqoo.
• Additionally, Yoshiyuki Aikawa, Waqoo's largest shareholder, is expected to transfer all remaining shares to SBCMG through an off-market transaction, also effective December 19, 2025.
• As a result of these transactions, SBCMG's total ownership of Waqoo's voting rights is expected to exceed 50% as of the settlement date, making SBC Medical the parent company and largest shareholder.
• The total investment for up to 575,052 shares is approximately JPY 1,092.5 million.

Sentiment

Score: 8

Explanation: The filing reports the successful completion of a strategic acquisition, leading to majority ownership in a target company that enhances R&D capabilities and market presence. This is a clear positive development for the company's strategic growth.

Positives

• Successful completion of the tender offer for Waqoo, Inc. shares.
• SBC Medical Group Holdings is expected to achieve majority ownership (over 50%) of Waqoo, Inc., making it a parent company.
• The acquisition strengthens SBC's comprehensive service offerings and R&D capabilities, particularly in regenerative medicine technologies.
• Expands SBC's healthcare technology capabilities and strengthens its presence in the Japanese market.
• The number of tendered shares (637,817) exceeded the maximum planned purchase volume (575,000), indicating strong interest.

Negatives

• Shares tendered in excess of the maximum planned purchase volume (575,000 shares) will not be purchased, requiring a pro rata allocation.

Risks

• Forward-looking statements are subject to various risks, uncertainties, assumptions, or changes in circumstances that are difficult to predict or quantify.
• Actual results may differ materially from current expectations due to factors such as changes in global, regional, or local economic, business, competitive, market, and regulatory conditions.
• Other risks are listed under the heading 'Risk Factors' in the Company's filings with the U.S. Securities and Exchange Commission (SEC).

Future Outlook

The Company does not expect any change to the plans, policies, or intentions described in the tender offer statement filed in Japan on November 14, 2025. SBC Medical Group Holdings will continue to evaluate its investment in Waqoo and take appropriate actions in accordance with applicable laws. The acquisition is expected to enhance SBC's ability to deliver comprehensive solutions and strengthen its presence in the Japanese market.

Management Comments

• Strategic acquisition strengthens SBC's comprehensive service offerings and R&D capabilities.
• The acquisition aligns with SBC Medical's strategic expansion and will enhance the Company's ability to deliver comprehensive solutions to its medical practice clients.

Industry Context

This acquisition positions SBC Medical Group Holdings to expand its footprint in the Japanese healthcare market, specifically in medical research and development, and regenerative medicine technologies. By acquiring Waqoo, Inc., SBC Medical enhances its capabilities in a high-growth segment, potentially allowing it to offer more advanced and integrated solutions to its medical organization clients, differentiating itself from competitors.

Comparison to Industry Standards

• The filing does not provide specific industry benchmarks or comparable acquisition multiples for similar transactions in the Japanese medical R&D or regenerative medicine sector.
• SBC Medical Group Holdings was selected for inclusion in the Russell 3000 Index in June 2025, indicating its growing presence in the U.S. equity market.
• SBC Medical Group Holdings operates a wide range of franchise businesses across diverse medical fields, including advanced aesthetic medicine, dermatology, orthopedics, fertility treatment, dentistry, AGA, and ophthalmology, which is a broad portfolio compared to many specialized medical groups.

Related Party Transactions

• Yoshiyuki Aikawa, the largest shareholder of Waqoo, Inc. and a special related party, is expected to transfer all of his remaining shares to SBC Medical Group Co., Ltd. through an off-market transaction outside of the Tender Offer, effective December 19, 2025.

Stakeholder Impact

• Shareholders (SBC Medical Group Holdings): Expected to benefit from enhanced R&D capabilities, expanded service offerings, and strengthened market presence in Japan.
• Shareholders (Waqoo, Inc.): Those who tendered shares successfully will receive JPY 1,900 per share. Those who tendered in excess of the pro rata allocation will not have all their shares purchased. The largest shareholder will complete an off-market transfer.
• Employees (Waqoo, Inc.): Waqoo will become a subsidiary of SBC Medical Group Holdings, potentially leading to integration or strategic alignment.
• Customers/Clients (SBC Medical Group Holdings): May benefit from more comprehensive solutions and advanced medical technologies, particularly in regenerative medicine.

Next Steps

• Settlement of the tender offer shares will commence on December 19, 2025.
• The off-market transfer of shares from Waqoo's largest shareholder to SBCMG will also be effective as of December 19, 2025.
• SBC Medical Group Holdings will continue to evaluate its investment in Waqoo and take any actions it considers appropriate in accordance with applicable laws.

Key Dates

Recommendation

The successful acquisition of a majority stake in Waqoo, Inc., a company specializing in regenerative medicine, represents a significant strategic advancement for SBC Medical Group Holdings. This move enhances their R&D capabilities, expands their service offerings, and strengthens their presence in the crucial Japanese market. The fact that the tender offer was oversubscribed indicates strong market interest in Waqoo, and the subsequent off-market transaction ensures SBC Medical achieves full control. This strategic expansion into a high-growth medical technology area, coupled with the company's existing diverse portfolio and recent inclusion in the Russell 3000 Index, positions it for strong future growth and makes it an attractive investment.

Keywords

SBC Medical Group, Waqoo Inc, Tender Offer, Acquisition, Regenerative Medicine, Healthcare Technology, Japan Market, Corporate Governance, SEC Filing, 8-K, Nasdaq, Tokyo Stock Exchange, Medical Research and Development